VALO Health Rho-Kinase Inhibitor Patent Granted April 28
Summary
USPTO granted patent US12612382B2 to VALO Health Inc. on April 28, 2026, covering a process for preparing 6-substituted-1-(2H)-isoquinolinones and intermediate compounds. The patented compounds are inhibitors of the Rho-kinase enzyme or can be used as intermediates in preparing such inhibitors, with 27 claims under CPC classification C07D 401/12. The patent application was filed on April 16, 2024, under application number 18636763.
About this source
Granted patents in USPTO classification C07D, covering heterocyclic organic compounds: the chemical core of most small-molecule drugs. Around 160 grants a month. Unlike applications, grants are enforceable. This feed is the best public-domain signal of which small-molecule compositions have just become defensible IP, which matters for generic entry timing, freedom-to-operate opinions, and competitive intelligence. Watch this if you practice pharma IP law, manage a drug discovery patent portfolio, advise on compound licensing, or scout ANDA opportunities as brand drugs approach loss of exclusivity. Recent grants cover apalutamide process improvements and bioactive phenolate ionic complexes.
What changed
USPTO granted patent US12612382B2 to VALO Health Inc. covering substituted 6-substituted isoquinoline oxide compounds and their use in preparing 6-substituted-1-(2H)-isoquinolinone compounds that inhibit the Rho-kinase enzyme. The patent contains 27 claims classified under C07D 401/12 and names eight inventors: Par Holmberg, Sumit Kumar, Matthew James Wathier, Huimin Zhai, Christophe Benelli, Xavier Bon, Boris Camuzat-Dedenis, and Fabien Rodier.
Affected parties in the pharmaceutical and biotechnology sectors developing Rho-kinase inhibitors or related compounds should review this patent for potential licensing needs or freedom-to-operate concerns. The patent provides VALO Health Inc. with enforceable intellectual property rights in the United States for these isoquinolinone compounds and their preparation processes.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Process for preparing 6-substituted-1-(2H)-isoquinolinones and intermediate compound
Grant US12612382B2 Kind: B2 Apr 28, 2026
Assignee
VALO HEALTH INC.
Inventors
Par Holmberg, Sumit Kumar, Matthew James Wathier, Huimin Zhai, Christophe Benelli, Xavier Bon, Boris Camuzat-Dedenis, Fabien Rodier
Abstract
The invention relates to substituted 6-substituted isoquinoline oxide compounds of formula (V)
and to a process for making them. The compounds of formula (V) can be used as intermediates for making 6-substituted-1-(2H)-isoquinolinone compounds of formula (I)
The compounds of formula (I) are inhibitors of the enzyme Rho-kinase, or can be used as intermediates in the preparation of further inhibitors of the Rho-kinase enzyme.
CPC Classifications
C07D 401/12
Filing Date
2024-04-16
Application No.
18636763
Claims
27
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.